AlphAIAlphAI — Financial news for AI agents
stocktitan.netNOV 22 min read

Tests for tiny traces of cancer rose 300% at Tempus, reaching about 12,000

Tempus reported Q3 2026 revenue of $411.5M, up 23% YoY, with Oncology volume growth at 32% and MRD tests rising 300% to ~12,000. Data & Apps revenue grew 33%. The company raised full-year revenue guidance and announced collaborations with Merck, Moderna, and BMS. Tempus also cleared FDA approvals for AI cardiology products and plans to acquire Personalis.

Original reporting
stocktitan.net
Published Nov 2, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$TEM
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

Med
01

Why it matters

The earnings beat and guidance raise expectations for continued growth in AI‑driven diagnostics, potentially lifting related stocks.

02

Market read

The earnings release provides fresh data on Tempus' growth trajectory, influencing health‑tech and biotech equities.

03

What to watch

Pending Personalis acquisition and new FDA clearances could drive future revenue beyond the current quarter.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Tempus Labs reported its Q3 2026 results, highlighting a 23% revenue increase, a 300% jump in MRD tests, and new strategic collaborations with Merck, Moderna and BMS.

Market effects

Sector

Strong growth in oncology diagnostics and data services may boost health‑tech sector sentiment.

Regional

US biotech and health‑tech stocks could see modest upside following the earnings beat.

Global

Limited; impact confined to US‑listed health‑tech and data‑analytics peers.

Counterpoint

What could challenge this read

Investors may question the sustainability of rapid MRD test growth given competitive pressures.

Key entities

  • company
    Tempus Labs

    AI‑driven precision medicine company reporting Q3 results.

  • partner
    Merck

    Strategic collaborator on neoantigen therapy.

  • partner
    Moderna

    Strategic collaborator on neoantigen therapy.

  • partner
    BMS

    Strategic collaborator on oncology data licensing.

Read at source← All news

StoryTempus AI posts record Q3 revenue, first adjusted profit and raises full‑year outlook

Also covered by

6 outlets

Related articles

NOV 3
$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.

finance.yahoo.com2 min
NOV 2
$TEMMedAI 8/10

Tempus AI (TEM): Oncology Volume Surge and Data Licensing Bookings Signal a Profitable Inflection

Tempus AI (TEM) reported Q3 2026 revenue of $411.5M, up 23% YoY, with adjusted EBITDA of $25.6M. Oncology revenue grew 28% to $172.6M, while Data and Applications revenue increased 33% to $108.1M. The company raised full-year revenue guidance to $1.60B-$1.605B and expects near-term catalysts from reimbursement improvements and the pending $1.7B Personalis acquisition.

news.alphastreet.com7 min